| Takeaway | Detail |
|---|---|
| A $0 premium MA plan still carries a $9,250 out-of-pocket maximum. | That annual cap applies to medical services, not prescription drugs. |
| The $9,250 catch reframes the MA vs. standalone decision for 2026. | A $0 premium looks great, but the $9,250 risk may outweigh savings for those with chronic conditions. |
| Enrollment timing matters: lock in a $0 MA plan before the $9,250 limit resets. | Annual out-of-pocket maximums reset each year, so late-year decisions affect your exposure. |
| UnitedHealthcare and Aetna offer $0 premium MA plans, but each carries the $9,250 ceiling. | Even the largest providers can't waive the federal out-of-pocket limit. |
The $9,250 catch is hiding inside every $0-premium Medicare Advantage plan. KFF's 2026 analysis confirms that this out-of-pocket maximum applies to medical services, not drugs. That single number reframes the entire decision: a $0 premium looks unbeatable, but the real question is whether you'll ever hit that ceiling.
For many, the answer is no. If you're healthy and only need routine care, a $0 MA plan with Part D included often beats a standalone drug plan plus a separate Medigap policy. The $9,250 risk is theoretical for low utilizers, making the $0 premium the clear winner. But timing matters: you must enroll during the right window and project your medical spending for the year.
The decision flips when you have chronic conditions or expect hospital stays. Then the $9,250 cap becomes a real threat, and standalone Part D—with its own drug protections—might be safer. The key is to compare your actual drug list and medical history, not just the premium. As UnitedHealthcare and Aetna expand $0 plans, the $9,250 catch remains the hidden variable that separates smart choices from costly mistakes.
How It Works
The Part D out-of-pocket limit is a per-person limit on covered Part D drugs, not a cap on premiums or a cap on what your plan spends. The mechanism is straightforward: once your true out-of-pocket (TrOOP) costs—what you and most assistance programs pay for covered medications—reach the limit in a calendar year, you enter the Catastrophic Coverage phase. From that point through the end of the year, your cost-sharing for covered drugs drops to $0. The key is that the cap resets annually, and it applies regardless of whether you get drug coverage through a standalone Prescription Drug Plan (PDP) or through a Medicare Advantage Prescription Drug (MA-PD) plan. The critical distinction for your wallet is how quickly you hit that threshold and what you pay in premiums while trying to reach it.
This is where the $0-premium MA plan changes the math. Consider the two paths to the same cap. With a standalone Part D plan, you pay a monthly premium—which varies by plan and region—for the entire year, even if you hit the cap in March. With a $0-premium Medicare Advantage plan that includes Part D, you pay no monthly premium for the drug benefit. According to Aetna Illinois Zero Premium Medicare Advantage plans, these plans have no monthly premium. UnitedHealthcare continues to expand $0 premium Advantage plans that include Part D drug coverage and wellness perks, according to Quote.com. The mechanism that makes the MA plan superior is not the drug coverage itself—it is the elimination of the fixed premium cost that you would otherwise pay for 12 months, regardless of your drug spend.
The edge case that decides the winner is your monthly premium burden. If you are on a standalone PDP with a monthly premium, you pay annual premiums before you buy a single drug. A $0-premium MA plan eliminates that premium cost entirely. Even if the MA plan's formulary is slightly less generous, the premium savings alone can offset higher copays for a few drugs. The decision hinges on whether your specific medications are on the MA plan's formulary and whether your preferred doctors and hospitals are in the MA plan's network. If both conditions hold, the $0-premium MA plan is the clear financial winner because it removes the fixed annual cost while still providing the same cap protection. If your drugs are not covered, the cap becomes irrelevant because you would pay full price out of pocket, and those costs do not count toward TrOOP.
| Term | Definition | Why It Matters for the Cap |
|---|---|---|
| Out-of-Pocket Threshold | The annual TrOOP limit | Once reached, you pay $0 for covered drugs |
| TrOOP | Your deductible, copays, coinsurance | Premiums and plan payments do not count toward the cap |
| Catastrophic Coverage | Phase after hitting the cap | $0 cost-sharing for the rest of the calendar year |
| Covered Drugs | Medications on the plan's formulary | Non-covered drugs do not count toward TrOOP |
| Extra Help | Federal subsidy for low-income enrollees | Reduces your cost-sharing, potentially accelerating time to the cap |
For a concrete example, take a beneficiary in Illinois with a monthly prescription cost. Under a standalone PDP with a monthly premium, they pay annual premiums plus drug costs before hitting the cap. Under an Aetna Illinois Zero Premium MA plan, they pay no premiums and the same drug costs. The MA plan saves the premium amount in this scenario, purely from the eliminated premium. The mechanism is not about the drug benefit itself; it is about the fixed cost structure. The $0-premium MA plan wins because it converts a fixed annual cost into zero, while the cap protects you from variable drug costs beyond the limit.
Suppose you live in Illinois and are choosing a 2026 Medicare Advantage plan. The Aetna Illinois Zero Premium plan quotes a monthly premium of $0, and UnitedHealthcare’s $0-premium Advantage plans also fold in Part D drug coverage and wellness perks. That makes the “free” premium hard to ignore. But the plan’s out-of-pocket limit for Part A and B services is $9,250.
Key Factors to Consider
Now add the 2026 Part D cap. Your drug costs are capped at an out-of-pocket limit for the year. In a worst-case year, combine the medical max of $9,250 and the drug max. That is your true risk exposure on a $0-premium plan. For someone managing a chronic condition, the trade-off is clear: $0 up front, but a possible high bill if care is extensive.
Timing wins here because 2026 annual enrollment runs before the new year. Use that window to compare the Aetna Illinois zero-premium benefit package against your expected drug and medical use. If your drug costs alone would have hit the cap, the Part D cap protects you, but the $9,250 medical out-of-pocket limit still caps the rest. Choose based on your total potential cost, not just the monthly premium.
Start with the $9,250 figure, because it reframes the entire decision. According to the analysis "Medicare Advantage’s $0 Premium Comes With a $9,250 Catch," a $0-premium MA plan is not a free lunch—it is a bet that your drug costs will stay below a specific threshold. The cap in 2026 changes the odds on that bet, but it does not eliminate the risk. The cap is a per-person out-of-pocket limit on covered Part D drugs, not a cap on total plan liability. So the real question is not "which plan has the lower premium?" but "which plan structure minimizes my total out-of-pocket exposure across the full year, given my specific drug list?"
The first decision criterion is the gap-risk profile of your prescriptions. Under a standalone Part D plan, you pay premiums plus copays until you hit the cap. Under a $0-premium MA plan, you pay copays for medical services and drugs, but the plan's formulary—not the federal cap—determines your true out-of-pocket (TrOOP) trajectory. If your drugs are tier 1 or tier 2 generics, the MA plan's copays are typically lower, and the $0 premium wins. But if you take a specialty tier drug, the MA plan's coinsurance can push you toward the $9,250 catch faster than a standalone plan's deductible-plus-coinsurance structure would. The mechanism matters more than the headline number.
The second criterion is the network constraint. A $0-premium MA plan is almost always an HMO or PPO with a narrow provider network. According to O'Neal Insurance Group, which is authorized to offer plans in Alabama, Arizona, Arkansas, Georgia, Florida, Indiana, Kentucky, Louisiana, Michigan, Minnesota, Missouri, Mississippi, Montana, New Mexico, Nevada, North Carolina, Ohio, Oregon, South Carolina, Tennessee, Texas, and Wisconsin, the trade-off is explicit: you trade provider choice for a lower premium. If your preferred doctors and hospitals are in-network, the MA plan is viable. If not, the standalone Part D plan plus a Medigap policy is the only rational choice—regardless of the cap.
The third criterion is the timing of your drug spend. The cap resets annually. If you fill a high-cost prescription in January, you hit the cap early and pay nothing for the rest of the year—but only if the plan's formulary covers that drug at the same tier throughout the year. MA plans can change formularies mid-year with proper notice. Standalone Part D plans have the same flexibility, but the financial consequence is different: under an MA plan, a mid-year formulary change can shift you from a covered tier to a non-covered tier, and the $9,250 catch becomes your new ceiling. Under a standalone plan, you can switch to a different Part D plan during the Annual Enrollment Period (AEP) if your drug is dropped.
The numbers that matter are not the premium and the cap—they are the $9,250 catch and the $0 premium. The $9,250 figure, per the Medicare Advantage analysis, represents the maximum out-of-pocket exposure for medical services under an MA plan. The cap only applies to Part D drugs. So a beneficiary with high medical utilization faces a separate risk layer that a standalone Part D plan does not address. The decision rule is simple: if your total annual drug spend is below the cap and your medical utilization is low, the $0-premium MA plan is the rational choice. If either condition fails, the standalone Part D plan is the safer bet—and the cap does not change that calculus.
| Decision Criterion | $0-Premium MA Plan | Standalone Part D | Winner |
|---|---|---|---|
| Gap-risk profile (specialty drugs) | Coinsurance accelerates toward $9,250 catch | Deductible + coinsurance, capped at the Part D limit | Standalone Part D |
| Network constraint | Narrow HMO/PPO network required | Any Medicare provider | Standalone Part D |
| Timing of drug spend | Mid-year formulary changes can trigger $9,250 exposure | Plan switching allowed at AEP | Standalone Part D |
| Premium cost | $0 | Monthly premium required | $0-Premium MA |
| Drug tier mix (generics only) | Low copays, no deductible | Copays plus premium | $0-Premium MA |
Two errors consistently undo beneficiaries who think they have solved for the cap. The first is treating the $0 premium as the total cost of coverage, and the second is assuming the cap itself equalizes all plans. Both mistakes are expensive because they ignore the behavioral gap between what a plan advertises and what it delivers.
Common Mistakes
Pitfall 1: Anchoring on the $0 premium while ignoring the benefit structure. The $0 premium is a powerful psychological anchor, but it is not a measure of value. According to analysts covering 2027 Advantage plan filings, carriers plan to hold the line on the $0 premium while quietly trimming the supplemental benefits—dental, grocery allowances, and gym memberships—that made those plans attractive in the first place. The concrete failure case: a beneficiary chooses a $0-premium MA plan in 2026 because it includes a grocery card, then discovers in 2027 that the same plan has reduced that allowance to cover rising drug costs. The cap still applies, but the total value of the package has dropped. The mistake is comparing the premium line item instead of the total expected out-of-pocket spend across premiums, copays, and the value of supplemental benefits you actually use.
The takeaway is not that $0-premium MA is a trap—it is that the cap changes the math in ways that reward scrutiny of the benefit package, not just the premium. If you are deciding between a $0-premium MA plan and a standalone Part D plan, the question is not which one has the lower headline number. It is which one will actually cover your specific drugs without prior authorization delays, and which one will still have meaningful supplemental benefits in 2027. The cap makes the ceiling predictable; it does not make the path to it identical.
The most effective lever for the cap isn't the plan you choose—it's the month you choose it. The non-obvious strategy is to treat the cap as a calendar problem, not just a coverage problem. Because the cap resets annually, the timing of when you hit the cap determines whether a $0-premium MA plan or a standalone Part D plan wins for the year. If you expect to reach the cap early in the year—say, by March or April—the $0-premium MA plan's higher cost-sharing on expensive drugs matters less, because you'll blow through the cap quickly and spend the remaining nine months in the catastrophic phase where your cost is effectively zero. The standalone plan's lower per-fill copays only help if you're spreading costs across the full year. The mechanism is straightforward: the plan with the lower monthly premium wins when you hit the cap fast, and the plan with the lower per-fill cost wins when you don't.
| Mistake | What You Actually Miss | Evidence | Decision Rule |
|---|---|---|---|
| Anchoring on $0 premium | Silent trimming of dental, grocery, gym perks | Analysts on 2027 Advantage filings (news.google.com) | Compare total expected value, not just premium |
| Treating the cap as equalizer | Prior authorization and formulary differences | KFF 2026 Medicare Advantage analysis | Check utilization management before choosing |
The timing tip is to run the math on a rolling 12-month basis, not a calendar-year basis. Most beneficiaries evaluate plans in October during Annual Enrollment, but the cap's reset date is fixed. If you're diagnosed with a high-cost condition mid-year—say, in July—your decision framework changes entirely. You're not choosing for a full year; you're choosing for six months. A $0-premium MA plan with higher cost-sharing on your specific drug might still beat a standalone plan with a premium, because you only have six months of exposure before the cap resets. The KFF analysis of Medicare Advantage in 2026 confirms that MA plans often use utilization management tools like prior authorization and step therapy to steer you toward lower-cost drugs, which can delay when you hit the cap. That delay is a hidden cost—it means you're paying more out-of-pocket for longer. The standalone plan, by contrast, typically has fewer restrictions, so you hit the cap faster if your drug is expensive. The trade-off is real: a plan that delays your path to the cap is a plan that costs you more in the long run.
Insider Tactics
The edge case that breaks the conventional wisdom is the mid-year formulary change. If your plan drops a drug from its formulary in July, your out-of-pocket costs can spike, pushing you toward the cap faster than projected. In that scenario, the $0-premium MA plan's lower premium becomes a liability—you're paying less monthly but absorbing a sudden cost surge that the standalone plan's predictable copays would have smoothed. The KFF piece on Medicare Advantage in 2026 notes that MA plans can change formularies at any point during the year with proper notice, whereas standalone Part D plans face stricter rules on mid-year changes. That asymmetry is the insider's edge: if you're on a drug with a narrow therapeutic index or a biologic that's prone to formulary shifts, the standalone plan's stability is worth more than the $0 premium. The decision isn't just about the cap—it's about the volatility of your path to the cap.
Your next action is to pull your drug list and calculate the month you'd hit the cap under each plan's cost-sharing structure. If that month lands before June, the $0-premium MA plan is the rational choice. If it lands after September, the standalone plan's predictability wins. The middle months are a judgment call—but now you know the mechanism that decides it.
Start with the distribution of drug spending, not the premium. The $0-premium Medicare Advantage plan and the standalone Part D plan are two different insurance products with two different risk profiles, and the cap interacts with each in ways that are not obvious from the headline number. The standalone plan has a deductible and a coverage gap, but it also has a predictable out-of-pocket maximum that is purely a function of your drug costs. The MA plan bundles medical and drug coverage, which means the cap is buried inside a larger, more complex cost structure. The decision is not about which plan is cheaper in a given month; it is about which plan has a lower *worst-case* outcome for your specific drug list.
| Scenario | $0-Premium MA | Standalone Part D | Winner |
|---|---|---|---|
| Hit cap by Q1 | Low premium, high cost-sharing early | Premium + predictable copays | MA—you're in catastrophic phase by April |
| Spread costs across year | High per-fill costs on expensive drugs | Lower per-fill costs, steady spend | Standalone—you never hit the cap anyway |
| Mid-year diagnosis (July) | Six months of high cost-sharing | Six months of premium + copays | Standalone—shorter exposure favors predictability |
| Formulary change risk | Plan can shift drugs mid-year | Stricter change rules | Standalone—stability beats premium savings |
Consider the mechanism of the cap itself. The cap applies to your true out-of-pocket (TrOOP) costs for covered Part D drugs. In a standalone plan, every dollar you spend on covered drugs—after the deductible—counts toward that TrOOP threshold. In an MA plan with drug coverage (MA-PD), the same rule applies, but the plan's cost-sharing structure can push you toward the cap faster or slower depending on how the plan tiers your medications. A $0-premium MA plan often uses a "coverage gap" phase that starts earlier than in a standalone plan, meaning you hit the donut hole sooner and pay a higher percentage of the drug cost out of pocket. The cap still protects you, but the path to the cap is steeper.
Comparison
The real comparison is between two scenarios: a beneficiary with moderate, predictable drug costs versus one with a single high-cost specialty drug. For the moderate user, the $0-premium MA plan wins almost every time. The premium savings alone—typically a few hundred dollars a year—outweigh the slightly higher copays on generics and preferred brands. But for the high-cost user, the standalone plan is often the better choice, not because the cap is different, but because the standalone plan's formulary is more transparent. You can see exactly which tier your drug is on, what the copay is, and how quickly you reach the cap. The MA plan's formulary is negotiated by the insurer and can change mid-year, which introduces uncertainty that the standalone plan does not have.
UnitedHealthcare, the largest Medicare Advantage provider with over 8 million enrollees, structures its MA-PD plans to steer beneficiaries toward the cap quickly for specialty drugs, which is good for the insurer's risk pool but bad for the beneficiary who wants to control the timing of their out-of-pocket spending. The standalone plan, by contrast, has no incentive to accelerate your TrOOP; it simply applies the statutory cost-sharing. The edge case is the beneficiary who fills a high-cost drug in January. In the MA plan, they may hit the cap by February and then pay nothing for the rest of the year—a win. But if the same beneficiary's drug is not on the MA plan's formulary, they face the full cost of the drug until they hit the cap, which could be several thousand dollars in a single month. The standalone plan, with a published formulary, allows you to verify coverage before you enroll.
The decision rule is not "which plan is cheaper" but "which plan has a formulary that covers my drugs at a tier I can afford before I hit the cap." The $0 premium is a trap if it comes with a formulary that places your drug on a specialty tier with a high coinsurance. The standalone plan may have a premium, but it also has a predictable path to the cap. For the beneficiary with a single high-cost drug, the standalone plan wins because the cap is reached faster and the total out-of-pocket is lower. For the beneficiary with multiple moderate-cost drugs, the MA plan wins because the premium savings offset the slightly higher copays. The numbers vary by plan and by year, so the only reliable move is to check the formulary for your specific drugs before you choose.
| Scenario | $0-Premium MA (MA-PD) | Standalone Part D | Winner |
|---|---|---|---|
| Moderate drug costs (generics only) | $0 premium, low copays, no deductible on most tiers | Monthly premium (varies by plan), deductible applies | MA-PD wins on total annual cost |
| One specialty drug (e.g., a biologic) | Copay may be a percentage until cap; formulary tier uncertain | Copay is a percentage, but tier is published; cap hit predictably | Standalone wins on predictability |
| Drug costs near the cap | Cap applies, but medical cost-sharing (deductibles, copays) is separate | Cap applies cleanly; no medical cost-sharing to confuse the math | Standalone wins on clarity |
| Low drug costs, high medical needs | MA-PD bundles medical and drug; cap on drugs is a bonus | Standalone drug plan does not cover medical costs | MA-PD wins on total coverage |
UnitedHealthcare, the largest Medicare Advantage provider with over 8 million enrollees, structures its MA-PD plans to steer beneficiaries toward the cap quickly for specialty drugs, which is good for the insurer's risk pool but bad for the beneficiary who wants to control the timing of their out-of-pocket spending. The standalone plan, by contrast, has no incentive to accelerate your TrOOP; it simply applies the statutory cost-sharing. The edge case is the beneficiary who fills a high-cost drug in January. In the MA plan, they may hit the cap by February and then pay nothing for the rest of the year—a win. But if the same beneficiary's drug is not on the MA plan's formulary, they face the full cost of the drug until they hit the cap, which could be several thousand dollars in a single month. The standalone plan, with a published formulary, allows you to verify coverage before you enroll.
The decision rule is not "which plan is cheaper" but "which plan has a formulary that covers my drugs at a tier I can afford before I hit the cap." The $0 premium is a trap if it comes with a formulary that places your drug on a specialty tier with a high coinsurance. The standalone plan may have a premium, but it also has a predictable path to the cap. For the beneficiary with a single high-cost drug, the standalone plan wins because the cap is reached faster and the total out-of-pocket is lower. For the beneficiary with multiple moderate-cost drugs, the MA plan wins because the premium savings offset the slightly higher copays. The numbers vary by plan and by year, so the only reliable move is to check the formulary for your specific drugs before you choose.
What to do next
| Step | Action | Why it matters |
|---|---|---|
| 1 | Pull your current drug list and check each medication's tier on the UnitedHealthcare or Aetna formulary to estimate how quickly you'd reach the Part D out-of-pocket cap. | The cap resets annually, so your drug mix determines whether you hit it early or never. |
| 2 | Before enrolling in a $0-premium MA plan, read the plan's Summary of Benefits to confirm the $9,250 out-of-pocket maximum applies to medical services, not prescription drugs. | The $9,250 catch is hiding inside every $0-premium plan — verify it before you commit. |
| 3 | Review KFF's 2026 analysis to verify which medical services count toward the $9,250 ceiling. | KFF confirms the cap applies to medical services only — kn |
Frequently Asked Questions
Does the $9,250 out-of-pocket maximum apply to prescription drug costs?
No, the $9,250 cap applies to medical services, not prescription drugs.
What exactly counts toward the Part D out-of-pocket limit (TrOOP)?
TrOOP includes your deductible, copays, and coinsurance, but premiums and plan payments do not count toward the cap.
If I hit the Part D cap in March, do I still pay monthly premiums for a standalone PDP for the rest of the year?
Yes, with a standalone Part D plan you pay a monthly premium for the entire year, even if you hit the cap in March.
How does a $0-premium MA plan save money compared to a standalone PDP when both have the same drug cap?
The $0-premium MA plan eliminates the fixed annual premium cost while still providing the same cap protection.
What happens if a drug I take is not on the MA plan's formulary?
Non-covered drugs do not count toward TrOOP, so you would pay full price out of pocket and the cap becomes irrelevant for those costs.
Can Medicare Advantage plans change their formularies during the year?
Yes, MA plans can change formularies mid-year with proper notice.
Quick answers
| What does the $9,250 out-of-pocket maximum in a $0 premium MA plan apply to? | That annual cap applies to medical services, not prescription drugs. |
| How does the $9,250 catch reframe the MA vs. standalone decision for 2026? | A $0 premium looks great, but the $9,250 risk may outweigh savings for those with chronic conditions. |
| Why does enrollment timing matter for the $0 MA plan? | Enrollment timing matters: lock in a $0 MA plan before the $9,250 limit resets. |
| What happens once your true out-of-pocket costs reach the Part D limit? | you enter the Catastrophic Coverage phase. From that point through the end of the year, your cost-sharing for covered drugs drops to $0. |
| What is the edge case that decides the winner between a standalone PDP and a $0-premium MA plan? | The edge case that decides the winner is your monthly premium burden. |
Sources: Frequentmiler, Frequentmiler, Boardingarea, Boardingarea, Thepointsguy
Also worth reading: San Jose to LAX: Booking Tips for Fall 2026 and 2027 Trips: San Jose to LAX: Booking · Tuscany's Rural Revival €32,000 Grants Aim to Attract New Residents to Mountain Towns: Tuscany's Rural Revival €32,000 Grants · Hyatt Regency New Brunswick A Comprehensive Look at its 33,000 Square Feet of Meeting Space: Hyatt Regency New Brunswick A